Core Insights - Passage Bio, Inc. has made significant progress in its clinical programs for genetic forms of frontotemporal dementia (FTD) and is on track to report updated interim safety and biomarker data in the first half of 2026 [1][2][5]. Recent Highlights - The company has enrolled the first three patients with FTD-GRN in Cohort 3 of the ongoing upliFT-D study, which will evaluate Dose 2 PBFT02 [5]. - The first patient with FTD-C9orf72 has been treated with Dose 2 PBFT02 in Cohort 4 of the upliFT-D study, which is expected to include up to five patients [5]. - A differentiated preclinical program for Huntington's disease is advancing, with a clinical candidate selection anticipated in the second half of 2026 [5]. Anticipated Upcoming Milestones - Updated interim safety and biomarker data from the upliFT-D study is expected to be reported in the first half of 2026 [5]. - The company plans to seek regulatory feedback on the registrational trial design for FTD-GRN in the first half of 2026 [5]. - A clinical candidate for Huntington's disease is expected to be declared in the second half of 2026 [5]. Financial Results - As of December 31, 2025, the company reported cash and cash equivalents of $46.3 million, down from $76.8 million in 2024, with an expected cash runway through the first quarter of 2027 [12]. - Research and development expenses for Q4 2025 were $5.4 million, and for the full year, they totaled $23.3 million, compared to $9.6 million and $40.2 million in the same periods of 2024, respectively [12]. - The net loss for Q4 2025 was $13.0 million, or $4.09 per share, while the net loss for the full year was $45.5 million, or $14.35 per share, compared to a net loss of $64.8 million in 2024 [12][15].

Summary of Passage Bio FY Conference Call Company Overview - **Company**: Passage Bio (NasdaqGS:PASG) - **Focus**: Development of gene therapies for neurodegenerative diseases, specifically frontotemporal dementia (FTD) and Huntington's disease Key Points Clinical Programs - **Lead Program**: PBFT02 for treating frontotemporal dementia (FTD) with the granulin mutation - **Preclinical Program**: Huntington's disease targeting CAG repeat expansion - **Cash Runway**: Expected to last until Q1 2027 with a cash balance of $46 million and a burn rate of $30 million to $35 million per year [2][25] Frontotemporal Dementia (FTD) - **Target Population**: Patients with granulin mutation; estimated 18,000 patients in the U.S. and Europe [3] - **Mechanism**: AAV1 gene therapy delivered via nonsurgical injection to cerebrospinal fluid (CSF) to increase progranulin levels, addressing lysosomal dysfunction and neurodegeneration [3][4] - **Clinical Trial Status**: Ongoing Phase I/II study with nine patients treated to date; two dose levels being evaluated [5][6] - **Safety and Efficacy**: Preliminary data shows robust increases in CSF progranulin levels, with Dose 1 achieving levels in the mid-20s, significantly above normal [12][14] - **Biomarkers**: Plasma neurofilaments show a 4% increase in treated patients compared to a 28%-29% annual increase in untreated patients, indicating slowed neurodegeneration [15][16] Safety Profile - **Adverse Events**: Generally well-tolerated; some serious adverse events (SAEs) reported, including venous sinus thrombus and liver function test (LFT) increases, managed with adjusted immunosuppression [16][17] - **Prophylactic Measures**: Future cohorts will receive anticoagulation therapy to mitigate thrombotic risks [17] Competitive Landscape - **Comparison with Competitors**: Other programs, such as Elektor's, faced challenges due to mechanisms that may not effectively deliver progranulin to lysosomes; Passage Bio's approach focuses on direct delivery to CSF [28][30] - **Differentiation**: Passage Bio's one-time therapy shows durability and higher target engagement compared to competitors, with a focus on treating patients earlier in the disease progression [18][19] Huntington's Disease Program - **Target**: MSH3 DNA repair protein to reduce CAG repeat expansion, with plans for an optimized intraparenchymal delivery approach [21][22] - **Clinical Candidate Timeline**: Expected to declare a clinical candidate in the second half of the year, with ongoing preclinical studies [23][46] Future Outlook - **Upcoming Data Releases**: Anticipated updates on safety and biomarker data for both Dose 1 and Dose 2 in the first half of the year [24][39] - **Regulatory Engagement**: Seeking feedback on registrational trial design for FTD-GRN to clarify approval requirements [25] Additional Insights - **Patient Selection**: Moving forward, the company will focus on patients with lower Clinical Dementia Rating (CDR) scores (0.5 and 1) to maximize treatment efficacy [11][31] - **Long-term Goals**: Aiming to establish a strong clinical profile for both FTD and Huntington's programs, with a focus on early intervention and effective delivery methods [44][45]

Core Insights - Passage Bio and PepGen are small-cap medical companies being compared based on various financial and operational metrics to determine which stock is more favorable [1][3][4]. Institutional Ownership - Passage Bio has 53.5% of its shares owned by institutional investors, while PepGen has 58.0% [1]. - Insider ownership stands at 5.0% for Passage Bio and 5.2% for PepGen, indicating a similar level of insider investment [1]. Analyst Ratings - Passage Bio has a consensus target price of $42.67, suggesting a potential upside of 363.26% [3][4]. - PepGen's consensus target price is $10.00, indicating a potential upside of 83.82% [3][4]. - Passage Bio has a stronger consensus rating with a score of 2.50 compared to PepGen's score of 2.33 [3]. Earnings and Valuation - Passage Bio reported a net income of -$64.77 million with an earnings per share (EPS) of -$14.40 [5]. - PepGen's net income is -$89.98 million with an EPS of -$2.82 [5]. - Passage Bio has a higher price-to-earnings ratio compared to PepGen, which is currently trading at a lower valuation [5]. Profitability - Passage Bio has a net margin of -102.09% and a return on equity of -52.97% [6]. - PepGen's net margin is -84.15% with a return on equity of -65.59% [6]. Risk & Volatility - Passage Bio has a beta of 1.86, indicating it is 86% more volatile than the S&P 500 [7]. - PepGen has a beta of 1.91, meaning it is 91% more volatile than the S&P 500 [7]. Summary - PepGen outperforms Passage Bio in 6 out of 11 factors compared [8].

Core Insights - Passage Bio, Inc. is actively enrolling patients in Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) for the ongoing upliFT-D clinical trial of PBFT02, recognizing the urgent need for disease-modifying therapies for frontotemporal dementia (FTD) [1][2] - The company has aligned with the FDA on an analytical approach to establish comparability of a high-productivity, suspension-based manufacturing process for PBFT02, which is expected to yield over 1,000 doses per batch with over 90% purity [5][2] - Passage Bio is on track to obtain regulatory feedback on the registrational trial design for FTD-GRN in the first half of 2026, with plans to report updated interim safety and biomarker data from Dose 2 during the same period [5][4] Recent Highlights - The upliFT-D trial is a Phase 1/2 global, multi-center, open-label clinical trial aimed at evaluating the safety and tolerability of PBFT02, with secondary endpoints including disease biomarkers and clinical outcome measures [6] - The trial protocol has been amended to allow for the enrollment of patients who are prodromal or have mild cognitive impairment, while excluding those with more severe progression [5] Financial Overview - As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $52.8 million, down from $84.8 million a year prior, with an expected cash runway into the first quarter of 2027 [11] - Research and Development (R&D) expenses for the third quarter of 2025 were $4.3 million, a decrease from $8.7 million in the same quarter of 2024 [11] - General and Administrative (G&A) expenses also decreased to $4.3 million from $7.3 million year-over-year [11] - The net loss for the third quarter of 2025 was $7.7 million, or $2.44 per share, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024 [11][16]

Core Viewpoint - Passage Bio, Inc. is actively engaged in the development of genetic medicines aimed at treating neurodegenerative diseases, with a focus on innovative one-time therapies [3]. Company Overview - Passage Bio is a clinical stage genetic medicines company dedicated to improving the lives of patients suffering from neurodegenerative diseases [3]. - The company's lead product candidate, PBFT02, targets conditions such as frontotemporal dementia by increasing progranulin levels to restore lysosomal function and slow disease progression [3]. Upcoming Events - Will Chou, M.D., the president and CEO of Passage Bio, will participate in a fireside chat at the Guggenheim Securities 2 Annual Healthcare Innovation Conference on November 12, 2025, at 9:30 a.m. ET in Boston, MA [1]. - A live webcast of the event will be accessible on the Investors & News section of Passage Bio's website, with a replay available for 90 days post-event [2].

Core Insights - Passage Bio, Inc. is a clinical stage genetic medicines company focused on neurodegenerative diseases [3] - The company will participate in the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025 [1] - The lead product candidate, PBFT02, aims to treat frontotemporal dementia by elevating progranulin levels [3] Company Overview - Passage Bio is dedicated to developing one-time therapies targeting the underlying pathology of neurodegenerative conditions [3] - The company emphasizes its commitment to improving the lives of patients and families affected by these diseases [4] Event Details - Will Chou, M.D., the CEO, will be part of a panel discussion at the conference [1] - A live webcast of the event will be available on the company's website, with a replay accessible for 90 days [2]

Summary of Passage Bio (PASG) FY Conference Call - September 05, 2025 Company Overview - Passage Bio is a clinical stage genetic medicines company focused on neurodegenerative diseases, particularly frontotemporal dementia (FTD) [2][3] Core Program: PBFT02 - PBFT02 is the lead clinical program targeting frontotemporal dementia with the GRN mutation, addressing a significant unmet need as there are no approved disease-modifying therapies for this condition [2][4] - The target population includes approximately 18,000 patients with GRN mutation FTD and 21,000 with C9orf72 mutation FTD across the U.S. and Europe [3] Clinical Development and Milestones - The ongoing phase 1/2 study of PBFT02 is a multicenter international open-label dose exploration study, currently active in the U.S., Canada, Portugal, and Brazil [7] - Key upcoming milestones include seeking regulatory feedback on manufacturing comparability in Q4 2025 and reporting dose two data in the first half of 2026 [3][21] Mechanism of Action - PBFT02 utilizes AAV gene therapy to increase levels of progranulin, a protein crucial for CNS cell homeostasis, which is deficient in patients with GRN mutation FTD [4][5] - The administration route is intracisterna magna, allowing for broad CNS biodistribution and lower doses compared to systemic delivery [9][10] Clinical Data and Safety Profile - Initial cohorts have shown promising results, with dose one achieving an average of over 25 nanograms per ml of progranulin levels at 12 months, indicating robust and durable responses [15][18] - The safety profile includes three serious adverse events (SAEs) among eight treated patients, with a decision to implement prophylactic anticoagulation for future patients due to observed venous thromboembolic events [12][20] Biomarker Analysis - Plasma neurofilament levels, a marker of neurodegeneration, showed a significant reduction in treated patients compared to the expected annual increase of 29% in untreated patients, suggesting a potential slowing of disease progression [17][20] - The study is also tracking CSF progranulin levels and clinical dementia rating scales to assess treatment efficacy [9][11] Competitive Landscape - PBFT02 is positioned as a potentially best-in-class therapy, with higher and more durable progranulin levels compared to other therapies in development for FTD [18][19] - Market research indicates a preference for a one-time therapy over monthly treatments, particularly for patients with behavioral dementia [19] Future Directions - Plans to expand the clinical study to include FTD C9 patients, as raising progranulin may also benefit TDP-43 pathology seen in multiple neurodegenerative diseases [20][21] - The company has a cash balance of $58 million, providing a runway into Q1 2027 to continue patient treatment and data collection [22] Conclusion - Passage Bio is advancing its clinical program for PBFT02 with promising early data and a clear regulatory pathway, aiming to address significant unmet needs in neurodegenerative diseases [22]

Company Overview - Passage Bio, Inc. is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases [3] - The company's lead product candidate, PBFT02, aims to treat neurodegenerative conditions such as frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression [3] Upcoming Events - Management will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - Will Chou, M.D., president and CEO, will present an overview of the company and engage in one-on-one meetings with investors [2] - A video webcast of the presentation will be available to registered attendees starting September 5, 2025, at 7:00 a.m. ET, and a replay will be accessible for 30 days post-event [2]

Core Insights - Passage Bio, Inc. reported updated interim data from the upliFT-D study, indicating that PBFT02 shows robust and durable elevation in cerebrospinal fluid (CSF) progranulin (PGRN) levels and improvement in plasma neurofilament light chain (NfL), a biomarker for disease progression [1][5] - The company has completed dosing of Cohort 2 in the upliFT-D study and submitted an amended protocol to global trial sites and health authorities [2][5] - As of June 30, 2025, the company has a cash position of $57.6 million, which is expected to fund operations into the first quarter of 2027 [4] Recent Highlights - The dosing of Cohort 2 in the upliFT-D study was completed, with a total of four FTD-GRN patients treated [5] - Interim data showed that Dose 1 PBFT02 treatment resulted in a significant increase in CSF PGRN levels, with the first patient treated with Dose 2 showing substantial increases at one month post-treatment [5] - The company plans to initiate enrollment of Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) once the amended protocol is approved [2][5] Financial Results - Research and Development (R&D) expenses for Q2 2025 were $5.8 million, down from $10.4 million in Q2 2024 [13] - General and Administrative (G&A) expenses for Q2 2025 were $4.5 million, compared to $6.5 million in Q2 2024 [13] - The net loss for Q2 2025 was $9.4 million, or $2.96 per share, a decrease from a net loss of $16.0 million, or $5.09 per share, in Q2 2024 [13][19] Anticipated Upcoming Milestones - The company seeks regulatory feedback on the suspension-based manufacturing process comparability in the second half of 2025 [5] - Updated interim safety and biomarker data from Dose 2 is expected to be reported in the first half of 2026 [5] - Regulatory feedback on the registrational trial design in FTD-GRN is anticipated in the first half of 2026 [5]

Core Viewpoint - Passage Bio, Inc. has announced a reverse stock split at a ratio of 1-for-20 to comply with Nasdaq's minimum bid price requirement of $1.00 per share, effective July 14, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 62,405,898 to about 3,120,295 [2]. - Proportionate adjustments will be made to the exercise prices and number of shares underlying the Company's equity awards and incentive plans [2]. - The reverse stock split will not change the number of authorized shares or the par value per share [2]. Group 2: Stockholder Information - Registered stockholders holding shares in book-entry form will not need to take action to receive post-split shares [3]. - Stockholders with shares in brokerage accounts will have their positions automatically adjusted, with no action required on their part [3]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive the nearest whole share [3]. Group 3: Company Overview - Passage Bio is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases [4]. - The lead product candidate, PBFT02, aims to treat conditions like frontotemporal dementia by elevating progranulin levels [4].